{
    "nctId": "NCT04993014",
    "briefTitle": "Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer",
    "officialTitle": "Circulating Tumor Cells and Adjuvant Treatment De-escalation After Neoadjuvant Therapy With Trastuzumab and Pertuzumab for HER2 Positive Early Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms, HER2-positive Breast Cancer, Circulating Tumor Cell",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "HER2 therapy disease-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HER2 positive breast cancer (hormone receptors positive or negative)\n* Stage I to III\n* Indication for neoadjuvant therapy with chemo (any regimen) + trastuzumab + pertuzumab\n* Breast surgery after neoadjuvant therapy\n* Preserved coagnition\n* ECOG 0-3\n* For the randomization phase: pathological complete response (ypT0/ypTis and ypN0)\n* Agreement on participation and signature of de ICF\n\nExclusion Criteria:\n\n* Contradindication for trastuzumab or pertuzumab\n* Adjuvant chemotherapy. Hormone therapy is allowed\n* Second primary tumor \\< 5 years, with an exception for treated non-melanoma skin cancer, and in situ cervical cancer",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}